APA aipamena

Schranz, J., Goldberg, L., Das, A. F., Alexander, E., Moran, G. J., Sandrock, C., . . . Gelone, S. P. (2019). 717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials. Open Forum Infect Dis.

Chicago Style aipamena

Schranz, Jennifer, Lisa Goldberg, Anita F. Das, Elizabeth Alexander, Gregory J. Moran, Christian Sandrock, Andrew F. Shorr, and Steven P. Gelone. "717. Lefamulin (LEF) Vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) At Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials." Open Forum Infect Dis 2019.

MLA aipamena

Schranz, Jennifer, et al. "717. Lefamulin (LEF) Vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) At Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials." Open Forum Infect Dis 2019.